This company listing is no longer active
BRAIN Biotech (BNND) Stock Overview
Provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BNND Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BRAIN Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.86 |
| 52 Week High | €6.08 |
| 52 Week Low | €5.86 |
| Beta | 1.44 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -45.74% |
| 5 Year Change | n/a |
| Change since IPO | -61.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| BNND | GB Chemicals | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | 0.7% |
| 1Y | n/a | -1.0% | 19.5% |
Return vs Industry: Insufficient data to determine how BNND performed against the UK Chemicals industry.
Return vs Market: Insufficient data to determine how BNND performed against the UK Market.
Price Volatility
| BNND volatility | |
|---|---|
| BNND Average Weekly Movement | n/a |
| Chemicals Industry Average Movement | 6.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BNND has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BNND's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 312 | Aryan Moelker | www.brain-biotech.com |
BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries.
BRAIN Biotech AG Fundamentals Summary
| BNND fundamental statistics | |
|---|---|
| Market cap | €130.21m |
| Earnings (TTM) | -€8.23m |
| Revenue (TTM) | €47.53m |
Is BNND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNND income statement (TTM) | |
|---|---|
| Revenue | €47.53m |
| Cost of Revenue | €21.22m |
| Gross Profit | €26.31m |
| Other Expenses | €34.54m |
| Earnings | -€8.23m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 55.35% |
| Net Profit Margin | -17.31% |
| Debt/Equity Ratio | 0% |
How did BNND perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/19 16:13 |
| End of Day Share Price | 2022/09/21 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BRAIN Biotech AG is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Schwarz | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Thomas Meyer | Baader Helvea Equity Research |